The Gleason grading system is one of the most important factors in clinical decision-making for prostate cancer patients, and is entirely based on the classification of tumour growth patterns. In recent years it has become clear that some individual growth patterns themselves have independent prognostic value, and could be used for better personalised risk stratification. In this review we summarise recent literature on the clinicopathological value and molecular characteristics of individual prostate cancer growth patterns, and show how these, most particularly cribriform architecture, could alter treatment decisions for prostate cancer patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756302 | PMC |
| http://dx.doi.org/10.1111/his.14214 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An Artificial Intelligence Model Using Diffusion Basis Spectrum Imaging Metrics Accurately Predicts Clinically Significant Prostate Cancer.
J Urol
January 2025
Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO.
Purpose: Conventional prostate magnetic resonance imaging has limited accuracy for clinically significant prostate cancer (csPCa). We performed diffusion basis spectrum imaging (DBSI) prior to biopsy and applied artificial intelligence models to these DBSI metrics to predict csPCa.
Materials And Methods: Between February 2020 and March 2024, 241 patients underwent prostate MRI that included conventional and DBSI-specific sequences prior to prostate biopsy.
xCT as a potential marker for neuroendocrine cells in high-risk prostate cancer and the relation to AL122023.1-miR-26a/30d/30e axis.
PLoS One
January 2025
Department of Anatomy, University Hospital Essen, Essen, Germany.
Prostate cancer is the second most common type of cancer in male worldwide. Stromal-epithelial interaction is thought to have a major impact on cancer development and progression. Previous studies have shown that interaction via soluble factors lead to a reduction in the expression of xCT and AL122023.
View Article and Find Full Text PDFComparing PSA Screening Patterns and Their Role as Predictor of Prostate Cancer Diagnosis: Analysis of a Contemporary North American Cohort.
Prostate
January 2025
VUI Center for Outcomes Research, Analysis, and Evaluation, Henry Ford Health System, Detroit, Michigan, USA.
Introduction: PSA screening remains a pivotal tool for early prostate cancer (PCa) detection. International guidelines rely on evidence from three major randomized clinical trials: ERSPC, PLCO, and CAP. We aim to examine the percentage of patients in real-world practice who get PSA screening as defined by each of the aforementioned trials.
View Article and Find Full Text PDFTrends in Prostate Cancer Incidence and Mortality Rates.
JAMA Netw Open
January 2025
Department of Epidemiology and Biostatistics, University of California, San Francisco.
Importance: Incidence of distant stage prostate cancer is increasing in the United States. Research is needed to understand trends by social and geographic factors.
Objective: To examine trends in prostate cancer incidence and mortality rates in California by stage, age, race and ethnicity, and region.
Stress regulatory hormones and cancer: the contribution of epinephrine and cancer therapeutic value of beta blockers.
Endocrine
January 2025
Department of Zoology, Institute of Science, Banaras Hindu University, Varanasi, Uttar Pradesh, India.
The word "cancer" evokes myriad emotions, ranging from fear and despair to hope and determination. Cancer is aptly defined as a complex and multifaceted group of diseases that has unapologetically led to the loss of countless lives and affected innumerable families across the globe. The battle with cancer is not only a physical battle, but also an emotional, as well as a psychological skirmish for patients and for their loved ones.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!